Noven Pharmaceuticals Inactive 10-Q2007 Q3 Quarterly report

Filed: 9 Nov 07, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: Abbott, abuse, accumulated, acid, adequacy, Aid, American, antidepressant, anxiety, apparent, arranging, arrive, assembled, assigned, assistance, attaining, Banner, bill, billed, billion, bipolar, breadth, briefly, buyer, buying, California, capsule, carbonate, certainty, Certified, cGMP, challenge, channel, chargeback, civil, Columbia, compete, complement, composition, compulsive, concurrently, consumer, consumption, contributory, coverage, criminal, criteria, daily, Daytrana™, defined, delivered, demonstrated, Depakote, depressive, destruction, directly, discount, doubtful, drawn, dual, earlier, ease, EITF, Electronic, eligibility, eligible, employment, encourage, endpoint, epilepsy, equivalent, ER, erode, escalating, evidence, exemption, expenditure, expertise, exposure, external, false, feasibility, feedback, focused, forecast, forecasted, formal, formulary, free, gelatin, good, government, governmental, group, handling, harm, high, hot, imprisonment, inaccurate, incremental, indefinite, induce, industry, inflated, influence, inhibit, inhibitor, Institute, institutional, introduction, invoice, Island, joining, knowingly, lag, lapse, lease, leasing, led, letter, lithium, low, Maine, maintenance, maker, manic, marked, Medicare, Mesafem, mesylate, methodology, Mexico, Michigan, migraine, monetary, monthly, motion, multiple, narrowly, needy, night, nonrefundable, obsessive, offer, offered, offering, Ohio, organized, ownership, panic, paroxetine, pattern, payor, penetration, Pexeva®, Pexeva®and, physically, population, preliminary, President, primary, processing, prohibit, prompt, proportion, proprietary, prosecuted, prosecution, prospectively, prove, Published, QD, qualitative, quantitative, reached, readily, rebate, rebated, recast, recommending, recoverable, refund, regularly, regulate, relevant, remuneration, rendered, rental, replace, replaced, resold, retail, Rhode, roughly, scope, scrutiny, seizure, selective, seller, serotonin, serum, shutdown, skilled, soft, Software, soliciting, Solvay, space, SSRI, stage, standard, statistical, statute, Stavzor, Stavzor™ER, submission, substitution, Synthon, tangible, temporary, treatment, trend, twelve, unclear, unrelated, unused, valproic, vasomotor, venue, Vermont, violated, Virginia, voluntary, vulnerable, West, wholesale, wholesaler, wide, willfully, withdrawal, withdrawn, York

Removed: approximate, assured, awarded, coordinate, earn, impacted, improvement, ordinary, targeting

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Noven Pharmaceuticals similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002

In connection with the Form 10-Q of Noven Pharmaceuticals, Inc. (“Noven”) for the three and nine months ended September 30, 2007 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Diane M. Barrett, Vice President and Chief Financial Officer of Noven, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Noven.

/s/ Diane M. Barrett
Name: Diane M. Barrett
Title: Vice President and Chief Financial Officer
Date: November 9, 2007